![Tom Wiedemann: American Cancer Society Golf Classic delivers on every metric, in every way](https://oncodaily.com/pub/uploads/2024/07/Screenshot-2024-07-22-at-11.01.21-1280x752.png)
Tom Wiedemann: American Cancer Society Golf Classic delivers on every metric, in every way
Douglas Flora recently responded to a post by Tom Wiedemann, CEO at AAA Club Alliance, on LinkedIn.
Quoting Tom Wiedemann’s post:
“As business leaders, we are frequently asked to participate in charity events and to serve on non-profit boards. When evaluating these opportunities, I consider a number of factors including Mission and Values, Performance and Impact, Financial Stewardship, and Personal Connection. I have been committed to the American Cancer Society Golf Classic for many years because it delivers on every metric, in every way.
I invite you to join me in supporting our efforts to win the fight against cancer. By bringing business and community leaders together for this event, we are creating champions of the American Cancer Society’s important mission.
Over the past 19 years, the Cincinnati Golf Classic has raised over $6 million to help the American Cancer Society continue to fund life-saving research as well as free programs and services for cancer patients and their families in our community and across the nation. With your participation, we can help put an end to cancer.
I hope to see you on the course!”
Quoting Douglas Flora’s post:
“Tom, thank you for your commitment and leadership. St. Elizabeth Healthcare and St. Elizabeth Physicians will be there for sure. Please consider supporting this important cause, this is a special event. Reach out to me if you’d like to get more involved.”
Sources: Douglas Flora/LinkedIn and Tom Wiedemann/LinkedIn
Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.
As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.